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Pain is frequent in patients with connective tissue diseases
(CTDs), particularly those affected by systemic sclerosis (SSc) and
systemic lupus erythematosus (SLE) in which it is virtually
ubiquitous and can have different causes. The SLE classiﬁcation
criteria include pain associated with musculoskeletal involve-
ment, which are frequently the initial symptom of SLE and can
include arthralgia, arthritis and/or myalgia. Chronic widespread
pain, the cornerstone of ﬁbromyalgia (FM), is also frequently
associated with CTDs.
Chronic pain has a considerable impact on mental health, and the
professional and family lives of patients. It can be due to many
disorders, but there are few reports concerning its prevalence
during the course of other diseases.
It is essential to identify the origin of pain in CTDs in order to avoid
dangerous over-treatment in patients with co-existing widespread
pain. Effective pain management is a primary goal of patient
care, although it has not been investigated in detail in patients
with SSc.
© 2015 Elsevier Ltd. All rights reserved.Medicine and Medical Specialities, Rheumatology Unit, Sapienza University
9; fax: þ39 02 39043454.
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M. Di Franco et al. / Best Practice & Research Clinical Rheumatology 29 (2015) 53e6254IntroductionConnective tissue diseases (CTDs) are characterised by multiple symptoms generally related to
organ injury. One of the most frequent is pain, the perception and threshold of which may be inﬂu-
enced by many biological, psychological and social factors interacting with the central and peripheral
nervous systems. It may be acute or chronic: acute pain is often primarily attributable to inﬂammation
and/or damage to peripheral structures (i.e. nociceptive input), whereas chronic pain (generally
deﬁned as lasting 3 months) is more likely to be due to input from the central nervous system (CNS).
The chronic nature of CTDs such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc),
which are often associated with pain and stress, can also trigger widespread chronic pain conditions
such as ﬁbromyalgia (FM).
Pain in systemic sclerosis
Systemic sclerosis (SSc, also known as scleroderma) is a severe rheumatic condition characterised
by skin thickening and internal organ ﬁbrosis [1] that is classically classiﬁed as limited cutaneous SSc
(lcSSc), which has rare organ involvement, and diffuse cutaneous SSc (dcSSc), which has a worse
prognosis and is characterised by rapid ﬁbrosis [1,2].
Pain is a ubiquitous problem in SSc, and may be caused by digital ulcers, Raynaud's phenomenon,
skin breakdown, joint contractures and/or gastrointestinal (GI) disrorders [3]. However, despite its
impact on the patients' quality of life, it has not been widely studied. In a large study published by the
Canadian Scleroderma Research Group, 85% of the 585 patients reported pain, which is correlated with
more frequent episodes of Raynaud's phenomenon, active ulcers, worse synovitis, and gastrointestinal
symptoms [4]; other authors have reported similar ﬁndings and that they correlate with a poor quality
of life [5e7].SSc and Raynaud's phenomenon
Raynaud's phenomenon (RP) is the most frequent and earliest manifestation of SSc. It is caused by
digital vasospasms usually triggered by exposure to cold or stress, which lead to the three phases of the
classical colour change from white to blue (cyanosis) and then red (erythema), and is frequently
associated with pain and sometimes with paresthesia, numbness and impaired hand function. It can be
effectively treated by various classes of drugs, whose beneﬁts include a reduction in the frequency and
severity of attacks, and the prevention and/or healing of digital ulcers. The ﬁrst-line non-pharmaco-
logical treatment of Raynaud's phenomenon involves avoiding or minimising exposure to cold, the use
of warm gloves, and avoiding aggravating factors such as smoking and certain drugs, although these
measures are more effective in the case of primary rather than secondary Raynaud's phenomenon.
Pharmacological measures usually start with calcium channel blockers but, if these are ineffective,
other options include topical nitroglycerin, and alpha adrenergic or angiotensin receptor antagonists.
Intravenous prostacyclin analogues are warranted in severe cases, particularly if there is a threat of
digital ischaemia, but they are expensive and, as they burdened by substantial risks (including the
induction of severe hypotension), close monitoring is required during their administration. Novel
approaches include the use of endothelin receptor antagonists, phosphodiesterase inhibitors and
statins, although their place in the therapeutic armamentarium remains to be established, and it may
also be possible to combine drugs acting on different target mechanisms, although this may be limited
by questions of cost.
Finally, surgical approaches (particularly thoracic sympathectomy) have fallen out of favour,
probably because of improvements in pharmacological treatments [8].SSc and digital ulcers
Often persistent and recurrent digital ulcers are one of the most frequent and burdensome clinical
manifestations, and occur in more than 50% of patients. They may simultaneously affect more than oneDownloaded for Anonymous User (n/a) at ASST Fatebenefratelli Sacco e Buzzi from ClinicalKey.com by Elsevier on May 08, 2019.
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prompted a number of researchers to seek the best treatment, and a very recent study published by
Giuggioli et al. tested the initial use of local lidocaine and prilocaine (25 mg of both per gram of 5%
EMLA cream), followed by local and oral morphine depending on the severity of the pain as measured
by means of a 10 cm visual analogue scale (VAS), and found that the deep wound debridement crucial
for healing was better tolerated [10].SSc and synovitis
Between 40% and 80% of SSc patients complain of musculoskeletal pain, which is more problematic
in patients with early diffuse SSc. The painmay not be sufﬁciently localised to attribute it to a particular
anatomical location, but a number of pain syndromes have been identiﬁed.
1. Tendinitis: Tendon friction rubs mainly affect patients with early diffuse SSc. They have a frequency
of 23e65%, but this tends to decline over time [11,12]. They are considered to be associated with
more active disease and worse outcomes.
2. Polyarthritis: Between 36% and 80% of patients complain of polyarthralgias, which may be more
frequent in those with early SSc, although some studies have found their occurrence
more equally distributed between limited and diffuse SSc [13]. The wide range of articular and
non-articular changes observed in radiographs of SSc patients go from juxta-articular osteo-
porosis and joint space narrowing to frank erosions in the metacarpophalangeal (MCP),
proximal interphalangeal (PIP), and distal interphalangeal (DIP) joints, and wrist. It has been
said that bony erosions (mainly in the hands) affect 4e57% of patients who have had SSc for
seven years, and joint space narrowing affects 16e92% [14]; however, concern has been raised
that some of the joint space narrowing may be related to concomitant osteoarthritis and not just
SSc.
3. Rheumatoid arthritis (RA): The recent availability of anti-cyclicitrullinated peptide (CCP) assays has
led to the ﬁnding that 1e15% of SSc patients have overlapping anti-CCP antibody-positive RA.
However, it should be noted that anti-CCP antibodies alone do not deﬁne RA, and it is not known
how many SSc patients without RA are anti-CCP positive.
4. Fibromyalgia (FM): Studies reported that 48% of patients had 11 or more tender points (TPs),
whereas the mean TP count was 7 (of 18) in the Malcarne study [15]. Clinical experience suggests
that FM is not uncommon in patients with SSc or other CTDs, and dedicated work is needed in this
ﬁeld, including studies using the 2010 ﬁbromyalgia criteria.
SSc and gastrointestinal disorders
The gastrointestinal (GI) is the second most frequently involved organ system in SSc patients
[16], who often experience complications such as gastro-esophageal symptoms, abdominal
pain and distension, weight loss and nutritional deﬁciencies, diarrhea, incontinence, and
constipation.
The esophagus is the most frequently affected part of the GI tract, and up to 90% of patients describe
symptoms of heartburn, regurgitation and dysphagia. These dysfunctions are probably due to smooth
muscle atrophy (particularly the inner circular layer of themuscularis propria) and ﬁbrosis affecting the
distal two-thirds of the esophagus but sparing the proximal part that causes the loss of normal neural
function. Lifestyle modiﬁcations and the avoidance of exacerbating food groups are often suggested
ﬁrst, but patients often need intensive treatment with proton pump inhibitors to control their
symptoms.
Up to 50% of SSc patients report early satiety, nausea, bloating, and abdominal discomfort. The
pathophysiology is not clear but it is possible that lymphocyte activation plays an important role in
causing smoothmuscle atrophy and collagen deposition, leading to severe ultrastructural alterations in
smoothmuscle cells and nerve ﬁbres. It is thought that gut dysfunction relates to a neuropathic process
in SSc patients [16].Downloaded for Anonymous User (n/a) at ASST Fatebenefratelli Sacco e Buzzi from ClinicalKey.com by Elsevier on May 08, 2019.
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lations with symptoms. Dietary modiﬁcations with the addition of a prokinetic agent is often the
mainstay of treatment, and probiotics may be useful in some patients. The use of metoclopramide can
improve gastric motility and motor activity, and somatostatin analogues such as octreotide have also
been used to induce contractile activity throughout the bowel. It has been reported that up to 18% of
patients with SSc are at high risk of malnutrition due to perioral sclerosis, esophageal dysmotility and
abdominal discomfort; the management of weight loss and malnutrition requires a multidisciplinary
team approach in which dieticians, nutrition specialists and ward nursing staff play a crucial role.
Diarrhea can affect up to 50% of patients, who need to be fully assessed because the cause is
multifactorial. Once the contributory causes of malabsorption have been investigated, symptomatic
approaches such as dietary measures to increase stool consistency and use of loperamide to inhibit
peristalsis and secretion can be tried; however, caution is required in order to avoid pseudo-
obstruction. Cholestyramine or other bile salt acid sequestrants may be helpful [16].
The colon and anorectum are the second most frequently affected parts of the GI tract, and it has
been suggested that the anorectal dysfunction reported by 50e70% of SSc patients is due to
neuronal dysfunction, smooth muscle atrophy and ﬁbrosis affecting the internal anal sphincter.
Fecal urgency can arise because of reduced rectal compliance and capacity due to collagen depo-
sition, and fecal incontinence has a signiﬁcantly negative impact on the patient's quality of life.
Practical specialist management such as biofeedback and bowel and pelvic ﬂoor muscle training can
be offered although the evidence is limited. Surgical repair of the anal sphincter has been
attempted but the long-term outcomes suggest worsening of continence and so this approach is not
generally advocated [16].
It has been reported that colonic involvement occurs in 20e50% of patients, who often lack the
post-prandial gastrocolic response mediated by the cholinergic pathway, thus reducing colonic
motility, prolonging colonic transit and leading to constipation. Unfortunately, laxatives frequently
offer little beneﬁt: stimulant laxatives rely on contact with the bowel mucosa, which is unpre-
dictable, and osmotic laxatives can aggravate bloating and discomfort. It has been shown that the
5HT4 receptor agonist prucalopride accelerates colonic transit but, although the results have been
promising, they have only been published in case reports. Opioid antagonists such as methylnal-
trexone do not seem to be very beneﬁcial in patients with SSc because of the nature of their bowel
dysmotility. Biofeedback training is useful in the case of idiopathic constipation, but it has not been
studied in SSc. There are no published data corning the effect of sacral nerve stimulation (SNS) on
constipation in SSc patients, although it is useful in idiopathic constipation; however, the draw-
backs of SNS are that it is an expensive invasive procedure associated with the risks of infection,
lead migration and pain.
Intestinal pseudo-obstruction is a rare GI manifestation of SSc. The treatment algorithms mention
professional patient counselling, and depressive symptoms have been reported to be associated with
GI involvement in SSc patients. Treating gastroenterologists should take an overall holistic approach
and their patients' quality of life, functional status and depressive symptoms, whereas treatment in-
terventions for SSc are limited [16].
Pain in systemic lupus erythematosus
SLE and inﬂammatory pain
Inﬂammation is the most frequent cause of pain in SLE patients. It is generally due to inﬂammatory
arthritis, which is included in the clinical set of the American College of Rheumatism (ARC) classiﬁ-
cation criteria [17,18]. The arthritis is typically not erosive, does not induce joint deformity, and
frequently precedes the other manifestations of SLE. It is associated with morning stiffness for more
than 30 min, can be evanescent or persistent, affects the knees and the small joints of hands (PIPs), and
produces objective evidence of inﬂammation (tenderness, swelling and effusion). A minority of
patients may show deforming reducible joint involvement of the hands (Jaccoud's arthropathy) [19].
The presence of synovitis is due to the production of cytokines such as interleukin (IL)-6, IL-17,
interferon (INF) alpha, IL-18, tumour necrosis factor (TNF) and B cell stimulating factor (BSF)-2, whichDownloaded for Anonymous User (n/a) at ASST Fatebenefratelli Sacco e Buzzi from ClinicalKey.com by Elsevier on May 08, 2019.
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criteria includes serositis, which may present as painful or painless pleural or pericardial effusion and
ascitis as a result of inﬂammation of the lining of lung, heart, and abdominal structures. Abdominal
pain is reported by 8e40% of SLE patients but may also be due to other causes, including mesenteric
vasculitis and pancreatitis [21,22].
SLE and neuropathic pain
SLE patients show a wide range of central nervous system (CNS) manifestations, including neuro-
psychiatric disorders and syndromes associatedwith the presence of auto-antibodies [23]. Although its
relationship with SLE is not clear, headache and migraine are reported by 32e66% of SLE patients and
may have various causes, including neuropsychiatric SLE (NPSLE) [24]. A recent study of 40 SLE patients
found that 70% experienced headache (tension type headache in 37.5%, migraine in 30%, cluster
headaches in 2.5%, and intracranial hypertension in 5%) but there was no association with disease
activity [25,26]. A close association with cognitive impairment, depression, pain and fatigue has been
found in NPSLE patients, but the underlying causes are unclear. Auto-antibodies cross-reacting with
DNA, N-methyl-D-aspartate receptors, and anti-endothelial and anti-phospholipid antibodies are the
most common factors associated with the pathogenesis of NPSLE [27].
It has been shown that peripheral neuropathies may be equally or even more frequent than some
CNS syndromes in SLE patients [28,29], and therefore another source of pain. A recent long-term study
of more than 2000 patients found that the prevalence of peripheral neuropathies was 5.9%, and that
66.7% of these were peripheral neuropathies due to SLE, of which sensory and sensorimotor axonal
polyneuropathies were the most frequent. Small-ﬁbre neuropathies and demyelinating poly-
neuropathies are other causes of peripheral neuropathy in SLE [30].
Neuropathic pain can be also a consequence of herpes zoster (HZ) infection, a painful neuro-
cutaneous disease caused by the reactivation of varicella zoster virus. Immunological studies of SLE
patients have shown abnormal T cell-mediated cytotoxicity, and the suppression of cellular immunity
may be involved in the pathogenesis of virus reactivation [31]. It is known that disease activity and the
use of corticosteroids and/or immunosuppressive therapies contribute to HZ infection, although a
study of a large cohort of SLE patients showed an annual HZ incidence rate of 6.4 events/1000 patient-
years without any association with disease activity (SLEDAI <8); post-herpetic neuralgia was detected
in 19% of the patients [32].
SLE and central pain
Musculoskeletal pain is reported by 50e90% SLE of patients during the course of the disease [33]
and chronic widespread pain, which affects 5e10% of the general population [34], by 65e80% of SLE
patients [35,36]. Until a few years ago, the pain associated with many rheumatic diseases was
considered to be peripheral in origin and induced by the well-known mechanisms of acute or chronic
inﬂammation, or morpho-structural alterations in the involved joints [37,38]. However, the mecha-
nisms underlying chronic widespread pain (the prototype of which is FM) have only recently been
identiﬁed as neurophysiological modiﬁcations in the perception, transmission and, above all, pro-
cessing of nociceptive afferents at the level of the CNS, which seem to be caused bywhat has come to be
called “sensitisation”: i.e. a permanent state of neuronal hyperexcitability that involves all of the
peripheral and central structures of the nociceptive system and causes hyperalgesia and allodynia
[39,40]. Immunological cascades may play a role in maintaining central sensitivity and chronic pain,
which is increased when CNS glial cells release pro-inﬂammatory cytokines; the traditional dichotomy
of inﬂammatory vs non-inﬂammatory pain may therefore be less appropriate than previously thought
[41]. The neurophysiological mechanisms underlying central sensitisation syndromes may also play a
role in causing the painful symptoms characterising CTDs. Patients with chronic pain conditions are
generally female and have experienced an early-life trauma or have a personal or family history of
chronic pain, or a personal history of other centrally mediated symptoms (insomnia, fatigue, cognitive
alterations andmood disturbances) and cognitions such as catastrophising, all of which can predict the
likelihood that acute pain will become chronic [42,43].Downloaded for Anonymous User (n/a) at ASST Fatebenefratelli Sacco e Buzzi from ClinicalKey.com by Elsevier on May 08, 2019.
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The clinical hallmark of FM is chronic widespread pain and tenderness to palpation of at least 11/18
tender points (TPs) [44]. Various symptoms are characteristically associated with FM, such as sleep,
mood and neurocognitive disorders, as indicated by the 2010 ACR classiﬁcation criteria [45]. The
estimated prevalence of FM in the general population is about 1e3% in different groups [46], and many
studies have investigated its prevalence in SLE patients, and evaluated how concomitant FM can in-
ﬂuence the symptoms and the activity of SLE. Morand et al. [47] found a 25.3% prevalence of FM in a
cohort of 87 SLE patients; Middleton et al. [48] a 22% prevalence in a group of 102 patients; and
Iannuccelli et al. [36] a prevalence of 33% in a cohort of 50 patients. The co-existence of FMmaymake it
difﬁcult to make a differential diagnosis with SLE ﬂares.
Themostwidely used indices for objectivelymeasuring SLEdisease activity are the British Isles Lupus
Assessment Group (BILAG) Index, the European Consensus Lupus Activity Measurement (ECLAM), and
the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), but none of these rates pain as such
[49]. The Systemic Lupus International Collaborating Clinics (SLICC) group has recently proposed a new
set of criteria that includes the speciﬁc clinical manifestations frequently reported by SLE patients. The
features of arthritis are speciﬁed because of the overlap between FM and SLE in some patients and it is
necessary to conﬁrm that there is joint line tenderness andnotmorediffuse allodynia. It is alsonecessary
topoint out that the causeof all the SLICC criteria is attributable to SLE andnot to anotherdiseaseprocess
or condition [50]. Middleton et al. [48] found that SLE patients with concomitant FM had signiﬁcantly
more frequent and severe symptoms, but there were no signiﬁcant difference in SLE activity measures
between the patientswith orwithout FM, and other authors have conﬁrmed the absence of correlations
between concomitant FM and disease activity, joint damage or organ dysfunction [50,51].
Fatigue is another symptom characterising FM and the most common constitutional and
debilitating symptom associated with pain in SLE patients [52], with prevalence rates of 50e80% [53].
Many studies have failed to demonstrate a correlation between fatigue and SLE disease activity, and
only a few have observed greater disease activity in patients reporting fatigue [36,53,54]. Moreover, SLE
patients with overlapping FM report symptoms such as headache, morning stiffness, diffuse alopecia,
and arthralgia signiﬁcantly more often [55].
The health-related quality of life (HRQoL) of SLE patients can be evaluated by administering ques-
tionnaires such as the Short-form 36 (SF-36) [56], and the Patient Acceptable Symptom State (PASS) a
simple questionnaire used to assess well-being in various rheumatic diseases including SLE [57].
Pain is associated with anxiety and depression, and perceptions of reduced physical functioning,
and so SLE patients need psychosocial interventions to relieve their pain and distress and improve their
coping skills [58]. Pain coping cognitions such as self-efﬁcacy for pain control and pain catastrophising
can inﬂuence symptoms such as pain, stiffness, fatigue, and psychological distress in SLE patients.
Recent data demonstrate that patients with low levels of self-efﬁcacy for pain control and/or high
levels of pain catastrophising report more physical symptoms and psychological distress, and highlight
the importance of assessing coping constructs in SLE patients [59]. Regardless of FM, pain inﬂuences
the quality of life, and SLE patients who have higher pain levels also report stiffness and fatigue. SLE
patients frequently report symptoms such as pain, fatigue and musculoskeletal distress, all of which
are related to low HRQoL scores [60] and cause functional limitations that lead to a signiﬁcant
economic burden. Theworking productivity of SLE patients with the highest levels of pain is lower than
that of SLE patients with less pain [61]. Consequently increased work absenteeism and work disability
(WD) rates have been observed in numerous SLE studies. The reportedWD rates range from 20% to 50%,
and vary widely among SLE population studies. The demographic factors associated with WD include
age, a low educational level, low socio-economic status and race, and correlations have been found
between WD and pain, fatigue, depressive symptoms, comorbidities, disease duration and activity,
joint damage and cognitive dysfunction [62]. The differential diagnosis of SLE and FM may be difﬁcult
because the two diseases have some symptoms in common, and low antinuclear antibody (ANA) titres
are frequently reported in the general population and FM patients, thusmaking it necessary to evaluate
patients clinically in order to avoid misdiagnoses.
Although secondary FM is not associated with SLE disease activity, it may worsen the quality of life
of patients with SLE, and requires appropriate treatment. It is necessary to assess whether pain in SLEDownloaded for Anonymous User (n/a) at ASST Fatebenefratelli Sacco e Buzzi from ClinicalKey.com by Elsevier on May 08, 2019.
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treatment with immunosuppressive drugs and steroids should be optimised on the basis of the
severity of the disease [63,64]. The correct interpretation of the FM symptoms is crucial to avoid over-
treatment because concomitant FM can simulate SLE ﬂares. Once it has been excluded that the pain is
attributable to disease activity, the same treatment as that used for FM can be administered. Analgesic
drugs such as acetaminophen or tramadol can be safely used in patients with widespread pain and SLE
[65]. Anti-epileptic drugs such as gabapentin and pregabalin have been approved for the treatment of
neuropathic pain: both drugs have favourable safety and tolerability proﬁles [66], and pregabalin has
also been approved by the American Food and Drug Administration (FDA) for FM. Low doses of tricyclic
antidepressants are useful in the case of musculoskeletal pain and headache. Selective serotonin and
serotonin norepinephrine reuptake inhibitors such as duloxetine (approved by the FDA for FM) can be
used in SLE patients with pain and depression [67].
Summary
Pain is frequently associated with CTDs. The pain in SLE can have various causes (e.g. inﬂammatory,
neuropathic and central pain), but inﬂammatory joint pain is one of the most frequent. Chronic wide-
spread pain is the cornerstone of FM, and many studies have investigated the prevalence of FM in SLE
patients, and evaluated how concomitant FM has a bearing on SLE symptoms and disease activity. The
treatment of pain in SLE patients requires a differential diagnosis; in particular, it is necessary to establish
whether the pain is localised or widespread, visceral or musculoskeletal. The ﬁrst step is to evaluate SLE
activity, and optimise speciﬁc SLE treatment with immunosuppressive drugs and steroids. FM symptoms
in an SLE patient may be misinterpreted as lupus disease activity and thus lead to over-treatment: when
it has been excluded that SLE activity is themain cause of pain, the treatment is the same as that used for
FM. Analgesic drugs such as acetaminophen or tramadol can be safely used in patients with widespread
pain and SLE. In many cases, non-pharmacological treatments such as aerobic exercise and cognitive
behavioural therapy may also be useful.
Pain is a virtually ubiquitous problem in SSc: 83% of patients in a recent large sample reported
signiﬁcant pain. Early in the disease process, patients report non-speciﬁc muscle pain and stiffness,
whereas other symptoms (e.g. difﬁculty in swallowing and gastrointestinal discomfort) emerge as the
disease progresses. Effective pain management is a primary goal of patient care, although it has not
been investigated in detail in patients with SSc.
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 Pain is a cornerstone of the definition of SLE and SSc, but it may be due to a mechanism
related to central pain sensitisation (similar to that observed in FM) and inflammation.
 Inflammatory pain symptoms can be reduced by NSAIDs and DMARDs, but many patients
continue to experience moderate pain due to alterations in central pain regulation mecha-
nisms, as in the case of CWP.
 It is important to identify the symptoms of CWP in order to be able to manage and treat
patients with CTDs appropriately.
 Effective pain management is a primary goal of patient care, although it has not been
investigated in detail in patients with SSc and SLE.
 Researchers and clinicians should be encouraged to assess perceived physical health, health
worries, mental health, and social support, in addition to routinely evaluating organ disease
severity in SSc and SLE patients.
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Research agenda
 To develop new laboratory and clinical indices for distinguishing CWP from inflammatory
pain in CTDs in order to reduce misdiagnoses.
 To evaluate the adequacy and appropriateness of measures for diagnosing inflammatory
and central pain.
 To determine whether new instrumental methods such as ultrasonography can distinguish
CWP from other types of pain.
 To develop new recommendations for differentiatingwidespread pain in the context of CTDs.
 To promote future multicentre studies and registries of widespread pain in CDTs in order to
reduce the overestimated disease activity.
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